We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...
There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Women with type 1 diabetes who are pregnant or planning a pregnancy should be offered a pregnancy-specific 'artificial pancreas' device. That is the recommendation in draft guidance published today by ...
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...
No two products are the same, so no two NICE Advice projects should be either. Andrew Walsh explains how NICE Advice adapts ...
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment TA1159 3 June 2026 3 June 2026 Durvalumab with chemotherapy for ...
Provide resuscitation and immediate emergency treatment for children, young people and adults who have convulsive status epilepticus (seizures lasting 5 minutes or more). If the person with convulsive ...
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Note: Healthcare students at universities which have an OpenAthens administrator can have an NHS OpenAthens account for the duration of their course. Students at these universities will have NHS ...
This guideline offers best‑practice advice on care and support for people living with dementia and their families and carers. The principles of person‑centred care underpin good practice in dementia ...
Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results